24 August 20112012 Prohibited List
Summary of Major Modifications and Explanatory Notes
INTRODUCTION
Members of the Anti-Doping Community should be aware that carefulconsideration has been given to all of the thoughtful comments that have been
provided in response to the distribution of the draft 2012 List. It will berecognized that not all suggestions have been accepted or incorporated into
the 2012 List but, as is explained below, modifications to the draft have been
made possible because of the contributions and submissions of many of ourcolleagues.
INTRODUCTORY SENTENCE• For clarity, the statement on Specified Substances now includes areference to the Code.

SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND
OUT-OF-COMPETITION)
PROHIBITED SUBSTANCES
S0: Non-Approved Substances••

S0 has been moved under “Prohibited Substances” to clarify that it does
not include “Methods”“i.e” has been replaced by “e.g” and more examples have been added.

This section has been moved under the heading Prohibited Substances in order toclarify that the scope of this provision relates only to substances and not to methods.
1Summary of Major Modifications
24 August 2011To broaden the scope of the section, “i.e” has been replaced by “e.g” and more
examples have been added to clarify the substances covered by this section.
Substances included in S0 are considered as specified.
As a reminder, it is stressed that if a designer drug or any other non-approved
substance falls into any of the S1-S9 categories (e.g. “similar chemical structure
and/or biologic effect”) then it will be deemed to be included in that section. Inclusion
in S0 applies only after all the other categories have been considered inadequate.
As a rule, a designer drug is defined as a synthetic analogue of a legally restricted or
prohibited drug, devised to circumvent drug laws.

S1. Anabolic Agents••

The IUPAC name of bolandiol (estr-4-ene-3β, 17β-diol) is now includedin S1.a.
Metabolites of DHEA (7α-hydroxy-DHEA, 7β-hydroxy-DHEA and 7-ketoDHEA) have been added to S1.b and it has been clarified that theendogenous metabolites is now an open list. The list of endogenous AAS
remains closed.

The INN will be used if existing; IUPAC nomenclature will also be used when necessary
for further clarity; common names will be added where considered helpful.

S2 Peptide Hormones, Growth Factors and Related Substances
As a reminder from the Explanatory Note for the 2011 List, Platelet-derived
preparations were removed from the List after consideration of the lack of any current
evidence concerning the use of these methods for purposes of performanceenhancement notwithstanding that these preparations contain growth factors. Despite
the presence of some growth factors, current studies on PRP do not demonstrate any
potential for performance enhancement beyond a potential therapeutic effect. Notethat individual growth factors are still prohibited when given separately as purified
substances as described in S.2.5

S3. Beta2-agonists:• Formoterol by inhalation up to a maximum daily therapeutic dose of 36
micrograms is included as an exception in the prohibited beta-2-agonists
section. If more than 30 ng/mL formoterol is detected in urine, this will
be considered an Adverse Analytical Finding unless the Athlete proves,through a controlled pharmacokinetic study, that the abnormal result
was the consequence of the use of the stated therapeutic inhaled dose.

2Summary of Major Modifications
24 August 2011

Taking into account recent research results and concerns expressed by members of theSport Community, inhaled formoterol at therapeutic doses is no longer prohibited.
Concerns continue to exist about the performance-enhancing effects of beta-2-agonists
when taken systemically and/or in large quantities.
The List prohibits theadministration of all beta-2-agonists except salbutamol (maximum 1600 micrograms
over 24 hours), formoterol (maximum 36 micrograms over 24 hours, expressed asinhaled/delivered dose) and salmeterol when taken by inhalation. Urinary thresholds
apply to the management of salbutamol and formoterol; work is ongoing to develop
thresholds for other beta-2-agonists. If there is a medical situation requiring doses
beyond those specified above, then a retrospective (emergency) TUE should besubmitted.
The issue of beta-2-agonists will continue to be the focus of WADA’s research activity
in order to ensure that the administration of large doses of these substances isprevented and prohibited, but that the appropriate care and treatment of asthmatic
athletes is facilitated. Ongoing surveillance of the use of these medications willcontinue as a priority; it is to be anticipated that there may be further changes in theway in which these substances are addressed in the future.

S4. Hormone and Metabolic Modulators• The title has been modified from “Hormone Antagonists and Modulators”
to “Hormone and Metabolic Modulators” to reflect the addition of a newsubsection.
• Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists (e.g. GW
1516) and PPARδ-AMP-activated protein kinase (AMPK) axis agonists(e.g. AICAR) have been re-categorized as substances that modify
cellular metabolism.
S5: Diuretics and Other masking agents•

Felypressin used in dental anaesthesia has been added as an exception
to the inclusion of products having a similar effect to desmopressin.

Glycerol is prohibited as a plasma expander which requires the ingestion of quantities
far beyond that which are commonly found in foodstuffs and toiletries

PROHIBITED METHODS
M2. Chemical and Physical Manipulation• Catheterisation has been removed as an example• The volume and frequency of intravenous infusions and/or injections
have been clarified as greater than 50 mL per 6 hour period.
3
Summary of Major Modifications
24 August 2011

• M2.3 has been reworded for clarification
M2.1: Catheterisation remains prohibited if used to tamper or attempt to tamper with theintegrity of a sample or sample collection. It is recognized that catheterization may benecessary for medical purposes.
M2.2: Attention is drawn to the fact that updated medical information is provided on the WADA
Website(http://www.wadaama.org/Documents/Science_Medicine/Medical_info_to_support_TUECs/WADA_Medical_info_IV_infusions_3.0_EN.pdf) to support the decisions of TUECs regarding the use of intravenous
infusions. For clarity, the volume and frequency of intravenous infusions/injections is included inthe List.
M2.3: To avoid any possibility of confusion with M2.2, the term “reinfusion” has been changed
to “reintroduction” in order to specify that any volume of blood readministered is prohibited. The
prohibition of “the sequential withdrawal, manipulation, and reintroduction of any quantity ofwhole blood” is not intended to prevent plasmapheresis, a specialized form of blood donation,and similar processes which are often undertaken by civic-minded Athletes and do not involve
the re-administration of whole blood; rather it specifically addresses the process in which an
Athlete’s blood is removed, treated or manipulated, and then reintroduced. Those undergoinghemodialysis, as part of the treatment of chronic kidney disease, will require a TUE for suchprocedures (and the substances that are often used to treat such disorders).

M3. Gene Doping•

To enable a more precise definition of Gene Doping, the examples inM3.3 have been re-categorized in S4.5.

SUBSTANCES AND METHODS PROHIBITED IN-COMPETITION
S6: Stimulants:•The note to adrenaline has been clarified with respect to its use.

As a reminder some stimulants may be available under several other names, forexample “methylhexaneamine”, sometimes presented as dimethylamylamine,pentylamine, geranamine, Forthane, 2- amino-4-methylhexane, geranium root extract
or geranium oil.

S9 Glucocorticosteroids
The section remains unchanged from the 2011 List insofar as the prohibited routes ofadministration of glucocorticosteroids are concerned. Surveillance of the use of thesesubstances continues and work is ongoing to develop threshold levels to assist in thedetection and management of these substances. It is to be anticipated that there will
be further changes in this section in the future. References to “Declarations of Use”
and “Therapeutic Use Exemptions” were removed in 2011.
4
Summary of Major Modifications
24 August 2011

SUBSTANCES PROHIBITED IN PARTICULAR SPORTS
P1. Alcohol•

At the request of Federation Internationale des Quilleurs (FIQ) alcohol isno longer prohibited in Ninepin and Tenpin Bowling.

P2. Beta-blockers•Bosbsleigh and Skeleton (FIBT), Curling (WCF), Modern Pentathlon(UIPM), Motorcycling (FIM), Sailing (ISAF), Wrestling (FILA) areremoved from the list of sports in which beta-blockers are prohibited.

WADA is re-evaluating the prohibition of beta-blockers in certain sports in conjunction
with the concerned federations and other stakeholders. This has led to the removal of
6 sports from this section.

MONITORING PROGRAM• In order to detect potential patterns of abuse, the following have been
added to the Monitoring Program:• In-competition: nicotine, hydrocodone, tramadol.
• Out-of-competition: glucocorticosteroids.

5
Summary of Major Modifications
24 August 2011